Accord Healthcare ready to fill UK COVID drug shortages
Accord Healthcare announces a significant change to the way the UK receives hydroxychloroquine (HCQ), a medicine under investigation during COVID-19.
Read More
Newsroom
Accord Healthcare addresses shortages of critical ventilator medicines for COVID-19 patients
The Department of Health and Social Care (DHSC) announced yesterday, 16 April 2020 that the UK’s supplies of the vital muscle relaxant medicines (atracurium and cisatracurium) used in patients on mechanical ventilators will be exhausted in the next few days via the MHRA.
Read MoreViva Italia
Our team in Italy were asked by Medicines for Europe and the ASSOGENERICI (Italian G
Read MoreAccord Healthcare in the News – BBC Feature 26 March 2020
Accord Healthcare featured on the BBC
Read MoreAccord donates two million tablets of hydroxychloroquine to largest COVID-19 trial in the world involving 40,000 frontline healthcare workers
Accord Healthcare Ltd is collaborating on a large multi-national study into the prevention of COVID-19 infection using hydroxychloroquine, a drug that may have an effect in preventing and/or reducing symptoms of COVID-19, in line with the WHO's targeted research priorities.
Read MoreSupporting the next generation of digital pharmacies
Online pharmacies are on the rise and their growth rate has doubled.
Read MoreFMD One Year on
Putting patients at the heart is what we believe in at Accord.
Read MoreLeading the conversation on Growth in Pharmaceuticals with Generics Bulletin and Scrip
Showcasing our expertise around innovative growth, Accord recently partnered with Generics Bulletin and Scrip to host a round table of pharma professionals including Clinigen, Mylan, BC Partners and Medichem to discuss growth in the industry.
Read MoreInternational suppliers meet at Accord Fawdon to celebrate growing together in partnership
Accord Fawdon recently hosted a special event to celebrate its supplier partnerships.
Read MoreForesee Pharmaceuticals Enters Exclusive License Agreement with Accord Healthcare
Taipei, Taiwan and Harrow, England, February 11, 2019 – An exclusive license agreement for the commercialisation of Foresee Pharmaceutical’s (6576.TWO) novel FP-001 program (leuprorelin depot), Leuprolide Mesylate Injectable Suspension (LMIS) ready-to-use subcutaneous depot formulations has been granted to Accord Healthcare.
Read More
